UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

Performance

52-Week Range 51.3% below 52-week high

24.75

16.5052W Low 50.8152W High

1 Week 29.2% below 1-week high

24.401W Low 34.971W High

UroGen Pharma Ltd. - Ordinary Shares (URGN) traded between $16.50 and $50.81 over the past 52 weeks and last traded at $24.75, 51.3% below its 52-week high. Over the past week it ranged between $24.40 and $34.97.

Past 12 Months

-28.0%

-39.2%

-47.3%

-15.8%

+9.0%

+5.1%

1W -$9.61

1M -$15.95

3M -$22.21

6M -$4.65

YTD +$2.04

1Y +$1.21

URGN was +5.1% over the past year, -15.8% over six months, +9.0% year to date, -28.0% in the last week.

12 Months vs Market

URGN

+5.1%

DIA

+9.2%

SPY

+9.7%

QQQ

+7.3%

IWM

+13.9%

Over the past 12 months URGN returned +5.1% versus DIA (Dow) +9.2%, SPY (S&P 500) +9.7%, QQQ (Nasdaq 100) +7.3% and IWM (Russell 2000) +13.9%.

Volume & Liquidity 1.74× 3-mo avg

Today 1,761,234 3-mo avg 1.0M

2.1M

1.3M

1.0M

900.9K

YTD

864.1K

895.5K

URGN most recently traded 1,761,234 shares against a 3-month average daily volume of 1.0M.

More News

UroGen (URGN) Q3 2026 Earnings Call Transcript ↗

November 04, 2026

Urogen Pharma (NASDAQ:URGN) Nears 52-Week High on Minervini Trend Template and High Growth Momentum Screen ↗

UroGen Pharma (NASDAQ:URGN) Falls After Q3 Revenue Miss and JELMYTO Guidance Cut ↗

November 04, 2026

Via Chartmill

UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup ↗

September 05, 2026

Via Chartmill

July 09, 2026

Via Chartmill

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

November 04, 2026

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

November 03, 2026

UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

November 02, 2026

UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer

October 28, 2026

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026

October 27, 2026

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

October 19, 2026

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 04, 2026

UroGen Pharma to Present at Upcoming Investor Conferences

September 02, 2026

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

August 20, 2026

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

August 17, 2026

UroGen (URGN) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Urogen Pharma Q2 Earnings Call Highlights ↗

August 05, 2026

Via MarketBeat

August 05, 2026

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

July 29, 2026

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

July 15, 2026

UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run ↗

July 12, 2026

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

July 08, 2026

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? ↗

June 30, 2026

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? ↗

June 14, 2026